Related Experiment Videos
[Standards and perspectives in locoregional hyperthermia]
Bert Hildebrandt1, Beate Rau, Johanna Gellermann
1Medizinische Klinik für Hämatologie und Onkologie, Campus Virchow Klinikum, Charitè Universitätsmedizin Berlin, Berlin, Deutschland. bert.hildebrandt@charite.de
Wiener Medizinische Wochenschrift (1946)
|June 9, 2004
Summary
Hyperthermia treatments, especially locoregional approaches, show synergistic effects with radiotherapy and chemotherapy. Recent advancements include hybrid MR-applicators and emerging combinations with novel therapies for cancer treatment.
Area of Science:
- Oncology
- Medical Physics
- Therapeutic Technologies
Context:
- Hyperthermia involves raising tumor tissue temperature to 40-43°C.
- Different methods exist: locoregional, perfusion, and whole-body hyperthermia.
- Efficacy varies by technique, indication, and application cost.
Purpose:
- To provide a critical update on locoregional hyperthermia indications.
- To highlight current clinical and technological advancements in hyperthermia.
- To review emerging hyperthermia combinations with novel therapies.
Summary:
- Hyperthermia alone has limited antineoplastic activity below 43-45°C but synergizes with radiotherapy and chemotherapy.
- 14 of 18 randomized trials support locoregional hyperthermia as an adjunct to standard treatments.
- Progress includes regional radiofrequency hyperthermia with multi-antenna and MR-applicator hybrid systems.
Impact:
- Advancements in regional radiofrequency hyperthermia, including hybrid systems, are now in clinical practice.
- Future applications involve combining hyperthermia with magnetic fluid hyperthermia, thermosensitive liposomes, immunotherapy, and gene targeting.
- This review offers insights into proven indications and cutting-edge progress in locoregional hyperthermia.